Myostatin and its Regulation: A Comprehensive Review of Myostatin Inhibiting Strategies

Mohammad Hassan Baig; Khurshid Ahmad; Jun Sung Moon; So-Young Park; Jeong Ho Lim; Hee Jin Chun; Afsha Fatima Qadri; Ye Chan Hwang; Arif Tasleem Jan; Syed Sayeed Ahmad; Shahid Ali; Sibhghatulla Shaikh; Eun Ju Lee; Inho Choi

doi:10.3389/fphys.2022.876078

Myostatin and its Regulation: A Comprehensive Review of Myostatin Inhibiting Strategies

Front Physiol. 2022 Jun 23:13:876078. doi: 10.3389/fphys.2022.876078. eCollection 2022.

Authors

Mohammad Hassan Baig¹, Khurshid Ahmad^{2

3}, Jun Sung Moon⁴, So-Young Park⁵, Jeong Ho Lim^{2

3}, Hee Jin Chun^{2

3}, Afsha Fatima Qadri², Ye Chan Hwang², Arif Tasleem Jan⁶, Syed Sayeed Ahmad², Shahid Ali², Sibhghatulla Shaikh², Eun Ju Lee^{2

3}, Inho Choi^{2

3}

Affiliations

¹ Department of Family Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.
² Department of Medical Biotechnology, Yeungnam University, Gyeongsan, South Korea.
³ Research Institute of Cell Culture, Yeungnam University, Gyeongsan, South Korea.
⁴ Department of Internal Medicine, College of Medicine, Yeungnam University, Daegu, South Korea.
⁵ Department of Physiology, College of Medicine, Yeungnam University, Daegu, South Korea.
⁶ School of Biosciences and Biotechnology, Baba Ghulam Shah Badshah University, Rajouri, India.

Abstract

Myostatin (MSTN) is a well-reported negative regulator of muscle growth and a member of the transforming growth factor (TGF) family. MSTN has important functions in skeletal muscle (SM), and its crucial involvement in several disorders has made it an important therapeutic target. Several strategies based on the use of natural compounds to inhibitory peptides are being used to inhibit the activity of MSTN. This review delivers an overview of the current state of knowledge about SM and myogenesis with particular emphasis on the structural characteristics and regulatory functions of MSTN during myogenesis and its involvements in various muscle related disorders. In addition, we review the diverse approaches used to inhibit the activity of MSTN, especially in silico approaches to the screening of natural compounds and the design of novel short peptides derived from proteins that typically interact with MSTN.

Keywords: MSTN inhibitors; myostatin; natural compounds; peptides; skeletal muscle.

Publication types

Review